NCT03696030View on ClinicalTrials.gov

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

February 19, 2026

Study Completion Date

February 19, 2026

Conditions
Malignant NeoplasmMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Neoplasm in the LeptomeningesBreast CancerHER2-positive Breast Cancer
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given HER2-CAR T cells via intraventricular administration

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

City of Hope Medical Center

OTHER